Key enzymes involved in de novo FAS, such as ATP citrate lyase (ACLY) and fatty acid synthase (FASN), are overexpressed in HCC, and their upregulation is associated with poor prognosis (48). The gene discussed is ACLY; the disease is hepatocellular carcinoma.